Synovial Fluid Bank From Arthritic Patients

Arthritis Clinical Trial

Official title:

Establishment of a Bank of Synovial Fluids and Paired Sera From Arthritic Patients for the Evaluation of New Methods Facilitating the Diagnosis and the Monitoring of Progression and Therapy of Arthritis.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00512343
• Other study ID #: 02-12 LS
• Status: Recruiting
• Start date: June 2002
• Est. completion date: September 2030

Study information

• Verified date: December 2023
• Source: Université de Sherbrooke
• Contact: Gilles Boire, MD, MSc
• Phone: (819) 564-5261
• Email: Gilles.Boire[@]USherbrooke.ca
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objectives of this group project is to collect synovial fluid (SF) and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.

Description:

Our group has developed interdisciplinary expertise in biomarkers related to distinct aspects of inflammation-induced joint damage, most notably those associated with degradation of components of the extracellular matrix, bone loss, or associated with post-translational changes on protease inhibitors.

The objectives of this group project is to collect SF and paired sera and carry out preclinical studies to evaluate, alone or by combination testings, the potential of novel biomarkers for their prevalence and diagnostic/prognostic values in patients with arthritis, and to determine how therapeutic intervention regulate their levels.

More specifically, we will study (1) biomarkers associated with osteoclastic bone resorption and synthesis/degradation of cartilage, (2) inhibitors of enzymes (calpastatin) that are preferentially targeted by rheumatoid patients, as well as (3) enzymes (e.g. Matrix Metalloproteinases (MMPs)) responsible for the cleavage of components of the articular cartilage.

Finally, we propose to characterize the repertoire of specific active proteases in the SF of arthritic patients concomitantly to the use biomarkers (neoepitopes of cleaved collagens) previously associated with cartilage destruction and synthesis to identify new targets for the development of protease inhibitors for the treatment of arthritis. Furthermore, our project will also provide the opportunity to test the potential of measuring the net proteolytic activity by Fluorescent-Activated Substrate Conversion as a method of monitoring disease activity and treatment efficiency in a clinical setting.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: September 2030
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 95 Years

Eligibility

Inclusion Criteria:

• Significant joint effusion

Exclusion Criteria:

• Hemorrhagic effusion

• Traumatic effusion

• Less than 3 ml total of collected fluid (used for routine analysis and culture)

• Inability or refusal to consent

Related Conditions & MeSH terms

• Arthritis

Locations

Country	Name	City	State
Canada	Centre hospitalier universitaire de Sherbrooke	Sherbrooke	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Gilles Boire	Canadian Arthritis Network

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y, Ghahary A. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007 Aug;34(8):1650-7. Epub 2007 Jul 1. — View Citation

Simard N, Boire G, de Brum-Fernandes AJ, St-Pierre Y. A novel approach to measure the contribution of matrix metalloproteinase in the overall net proteolytic activity present in synovial fluids of patients with arthritis. Arthritis Res Ther. 2006;8(4):R12 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Availability of paired synovial fluid and serum samples for exploratory studies	Availability of paired synovial fluid and serum samples, linked with anonymized clinical and treatment data, from patients suffering from various arthritides (rheumatoid arthritis, gout and other microcrystalline arthritides, osteoarthritis, spondylarthropathies, juvenile idiopathic arthritis, and various other diseases, including inflammatory polyarthritis of recent-onset in adults	Use with various collaborators at different times, upon request and approbation